United States
                     Securities and Exchange Commission
                            Washington, DC 20549

                              FORM 10-QSB/A-1

               Quarterly Report Under Section 13 or 15(d) of
                    the Securities Exchange Act of 1934

For the Quarter Ended                                Commission File Number
  December 31, 2000                                            0-30935

                              NOVAMEX USA LTD.
           (Exact name of registrant as specified in its charter)

                                   OREGON
       (State or other jurisdiction of incorporation or organization)

                                 98-0198290
                    (I.R.S. Employer Identification No.)

                         360 rue Franquet, Suite 10
                         Sainte-Foy, Quebec, Canada
                  (Address of principal executive offices)

                               (418) 652-9001
            (Registrant's telephone number, including area code)

        Securities registered pursuant to Section 12 (b) of the Act:

                                    None

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.

          Yes     X   No
     -----     -----
State the number of shares outstanding of each of the registrants classes
of common equity, as of the latest practicable date.

Common stock, par value $.001; 10,500,000 shares outstanding as of
September 10, 2001.
ITEM 1.  FINANCIAL STATEMENTS

NOVAMEX USA LTD AND SUBSIDIARY
(A DEVELOPMENT STAGE COMPANY)
---------------------------------------------------------------------------
CONSOLIDATED BALANCE SHEET (in U.S. dollars)
---------------------------------------------------------------------------
<Table>
<Caption>
                    ASSETS
                                                  December 31      June 30
                                                        2000        2000
                                                 ------------  ------------
<S>                                             <C>           <C>
CURRENT ASSETS
  Cash                                           $       817   $    12,929
  Accounts receivable                                 13,452        17,952
  Advances to a related company                            -           250
  Advances to directors non-interest
   bearing and without specific terms of
   repayment                                               -         7,798
  Research and development tax credit
   receivable                                          5,809         5,698
  Prepaid expenses                                         -           978
                                                 ------------  ------------
                                                      20,078        45,605

EQUIPMENT - net of amortization                       18,357        20,656

  Proprietary technology                                   1             1
                                                 ------------  ------------
                                                 $    38,436   $    66,262
                                                 ============  ============
                                LIABILITIES
CURRENT LIABILITIES

  Accounts payable and accrued liabilities       $   307,100   $   286,668

  Due to an individual, non-interest bearing
   and without specific methods of repayment          64,425        65,246
                                                 ------------  ------------
                                                     371,525       351,914

DEFERRED INCOME TAXES                                  3,587         3,634
                                                 ------------  ------------
                                                     375,112       355,548
                    DEFICIENCY IN ASSETS
CAPITAL STOCK

  Preferred stock, $0.10 par value, 1,000,000
   shares authorized voting and participating,
   no shares outstanding:                                  -             -
   Common stock, no par value, 100,000,000
    shares authorized, voting and participating,
    10,500,000 issued, outstanding and paid              332           332

DEFICIT ACCUMULATED DURING THE DEVELOPMENT STAGE    (336,691)     (288,072)

ACCUMULATED OTHER COMPREHENSIVE INCOME                  (317)       (1,546)
                                                 ------------  ------------
                                                    (336,676)     (289,286)
                                                 ------------  ------------
                                                 $    38,436   $    66,262
                                                 ============  ============
</Table>
NOVAMEX USA LTD AND SUBSIDIARY
(A DEVELOPMENT STAGE COMPANY)
---------------------------------------------------------------------------
CONSOLIDATED STATEMENT OF INCOME AND DEFICIT
(in U.S. dollars)
Period ending December 31
---------------------------------------------------------------------------
<Table>
<Caption>
                                            From                              From
                                          July 31,                          July 31,
                                            1996                              1996
                                        (inception)                       (inception)
                                          through                           through
                                          December                          December
                            2000          31, 2000          1999            31, 1999
                  (3 months)  (6 months)            (3 months) (6 months)
                  ----------  ---------- ---------- ---------- ----------  ----------
<S>              <C>         <C>        <C>        <C>        <C>         <C>
EXPENSES
  Operating       $  13,146   $  29,850  $ 149,170  $  17,832  $  20,794   $  33,660
  Less research
   and development
   tax credits            -           -     (5,698)         -          -           -
  Selling               286         286     19,822      1,772      5,461      14,431
  Administrative     16,647      25,932    417,606      5,604      6,536     106,087
  Financial             674         775      6,104      1,175      2,419       4,406
  Loss (gain)
   on foreign
   exchange             799      (2,020)    (2,768)       203         82         316
                  ----------  ---------- ---------- ---------- ----------  ----------
                     31,552      54,823    584,236     26,586     35,292     158,900

LESS revenues
  realized
  during
  development
  stage               1,562       6,204    251,732      5,176      5,176       5,623
                  ----------  ---------- ---------- ---------- ----------  ----------
                     29,990      48,619    332,504     21,410     30,116     153,277
INCOME TAXES
  Current
   (recovered)            -           -        (98)         -          -         (98)
  Deferred                -           -      4,285     (3,247)    (4,593)    (29,688)
                  ----------  ---------- ---------- ---------- ----------  ----------
NET LOSS             29,990      48,619    336,691     18,163     25,523     123,491

DEFICIT AT
  BEGINNING
  OF PERIOD         306,701     288,072          -    105,328     97,968           -
                  ----------  ---------- ---------- ---------- ----------  ----------
DEFICIT AT
  END OF PERIOD   $ 336,691   $ 336,691  $ 336,691  $ 123,491  $ 123,491   $ 123,491

PER SHARE

Loss per
 common share         0.003       0.005       0.03      0.002      0.002        0.01

Weighted average
 number of common
 shares
 outstanding     10,500,000  10,500,000 10,500,000 10,500,000 10,500,000  10,500,000

</Table>
NOVAMEX USA LTD AND SUBSIDIARY
(A DEVELOPMENT STAGE COMPANY)
---------------------------------------------------------------------------
CONSOLIDATED STATEMENT OF CASH FLOWS
(in U.S. dollars)
Period ending December 31
---------------------------------------------------------------------------
<Table>
<Caption>

                                       2000                  1999
                               --------------------- ----------------------
                               (3 months) (6 months) (3 months)  (6 months)
                               ---------- ---------- ----------  ----------
<S>                           <C>        <C>        <C>         <C>
CASH PROVIDED BY (USED IN)

OPERATIONS
  Net loss                     $ (29,990) $ (48,619) $ (18,163)  $ (25,523)
  Items not involving cash
   Amortization                    1,001      2,033          -           -
   Deferred income taxes               -          -     (3,247)     (4,593)
                               ---------- ---------- ----------  ----------
                                 (28,989)   (46,586)   (21,410)    (30,116)
Change in non cash operating
working capital:
  Accounts receivable,
   advances to a related
   company and directors           5,468     12,185     (5,737)     (6,264)
  Income taxes receivable              -          -          -         100
  Prepaid expenses                   475        964          -           -
  Accounts payable and
   accrued liabilities            18,080     22,467      9,172      10,573
  Research and development
   tax credits receivable           (180)      (183)         -           -
  Advances from directors              -          -       (387)     (1,082)
  Advances from an individual        155       (743)     6,172       8,873
                               ---------- ---------- ----------  ----------
Net cash used in operating
activities                        (4,991)   (11,896)   (12,190)    (17,916)
                               ---------- ---------- ----------  ----------
INVESTING
  Additions of equipment               -          -       (557)     (1,056)
                               ---------- ---------- ----------  ----------
Net cash used in investing
activities                             -          -       (557)     (1,056)
                               ---------- ---------- ----------  ----------
FINANCING
 Change in bank loan                   -          -     10,186      20,299
                               ---------- ---------- ----------  ----------
Net cash provided by
financing activities                   -          -     10,186      20,299
                               ---------- ---------- ----------  ----------
CASH INCREASE (DECREASE)          (4,991)   (11,896)    (2,561)      1,327

CURRENCY TRANSLATION
 ADJUSTMENT ON CASH                   97       (216)       234         115

CASH AT BEGINNING OF PERIOD        5,711     12,929      6,572       2,803
                               ---------- ---------- ----------  ----------
CASH AT END OF PERIOD          $     817  $     817  $   4,245   $   4,245
                               ========== ========== ==========  ==========
</Table>

NOVAMEX USA LTD AND SUBSIDIARY
(A DEVELOPMENT STAGE COMPANY)
---------------------------------------------------------------------------
STATEMENT OF OTHER COMPREHENSIVE
INCOME (in U.S. dollars)
---------------------------------------------------------------------------
Period ending December 31
<Table>
<Caption>
                                       2000                   1999
                               --------------------- ----------------------
                               (3 months) (6 months) (3 months)  (6 months)
                               ---------- ---------- ----------  ----------
<S>                           <C>        <C>        <C>         <C>

Balance at beginning
  of period                    $     295  $  (1,546) $  (1,904)  $  (2,626)

Effect of translation
  during period                     (612)     1,229     (2,310)     (1,588)
                               ---------- ---------- ----------  ----------
Balance at end of period       $    (317) $    (317) $  (4,214)  $  (4,214)
                               ========== ========== ==========  ==========
</Table>

ITEM 2.  Management's Discussion and Analysis of Financial Statements

     This Form 10-QSB contains certain forward-looking statements.  For
this purpose any statements contained in this Form 10-QSB that are not
statements of historical fact may be deemed to be forward-looking
statements.  Without limiting the foregoing, words such as "may," "will,"
"expect," "believe," "anticipate," "estimate" or "continue" or comparable
terminology are intended to identify forward-looking statements.  These
statements by their nature involve substantial risks and uncertainties, and
actual results may differ materially depending on a variety of factors.

General

     Novamex USA Ltd. (the "Company"), was originally incorporated in the
state of Oregon on February 12, 1991 under the name International Business
Development Ltd. The Company was organized and authorized to pursue any
lawful purpose or purposes. The Company amended its Articles of Incorporation
on June 23, 1998, changing its name to Novamex USA Ltd. The Company has had
limited revenues and is considered to be a "development stage company."

     The Company operates in the biotechnology industry. The Company develops
and manufactures detection kits mainly to non-clinical industry segments
including the agri-food  and veterinary segments.  Non-clinical methods of
testing and detection include those that are not intended to be used for
establishing a clinical diagnosis.  These non-clinical methods are usually
used in house for self control purposes and are most prominently used in the
food industry to better control microbial contamination during processing.
To be useful, however, these methods must meet acceptable performance
criteria.

     The Company uses antigen-antibody reaction technology and employ rapid
diagnostic methods in their detection tests.  The Company has developed
unique testing methods in which any detectible reaction takes place entirely
inside a plastic cassette. Their tests also have other benefits of the rapid
diagnostic methods such as no incubation or washing steps.  Tests developed
by the Company produce results in approximately fifteen minutes.


     Test results are read visually using a colorimetric reaction.  Moreover,
these methods do not need any sophisticated equipment and may be carried out
as field tests by workers having no laboratory training.  The average cost
for a test is between U.S. $4.50 and $7 per sample. The Company has developed
timely, affordable tests that do not compromise accuracy.  The Company's
evaluation  results have established 99.4% accuracy rating on many of its
detection tests, although such accuracy ratings have been established by the
Company in its controlled environment.

     The tests have a shelf life of approximately 14 months when stored at
four degrees Celsius (4 C).  Each test uses enzymes or colored particles
coupled with specific antibodies.  Any reaction between antibodies and
antigens are revealed by adding a chromogenic substance (pigment producing
micro-organism) to the sample.  If a reaction has taken place, or in other
words the test is positive, the test will yield a blue color that is visible
to the naked eye.

     The general hygiene kit is the only test kit currently commercialized
and it has produced limited revenue since September of 1999.  This kit does
not require any special equipment and can be performed by anyone with minimal
training.  These tests have advantages over other popular hygiene tests that
are often costly, difficult to interpret and may give variable or
inconsistent results.  This test currently represents the largest source of
revenue for the Company.  The Company is currently developing approximately
six other test kits and has plans to research and develop three additional
kits.

Liquidity and Capital Resources

     At December 31, 2000, the Company had cash of $817 on hand.  The Company
has limited capital resources and is substantially dependent upon sales
proceeds from the Company's general hygiene test kit to meet its capital
requirements.  Sales from the hygiene test kit are the only source of revenue
and currently will not provide sufficient capital through the development
stage.  As a result, the Company may need to seek additional capital through
traditional bank loans, a private offering of common stock or another form of
debt or equity financing. If the Company is not successful in raising
sufficient capital through any of the aforementioned options, the ability of
the Company to meet its financial obligations in a timely manner or to remain
in business is doubtful.

Results of Operations

     Comparison of the three months ended December 31, 2000 and the three
     months ended December 31, 1999.

     During the second quarter of fiscal 2000, the Company's net cash used in
operations was $4,991 compared to $12,190 during the second quarter of fiscal
1999 the decrease is mostly due to the change in accounts receivable and
advances to a related company. There has also been an increase in the second
quarter 2000 operating  loss of $29,990 compared to an operating loss of
$18,163 for the second quarter ending December 31, 1999 due to increased
research and development efforts.

     The Company realized revenues in the amount of $1,562 in the second
quarter of fiscal 2000 compared to $5,176 of revenue in the same quarter of
1999.  The decrease in revenue realized was due to the Company's increased
efforts to research and develop test kits and corresponding decrease in
efforts to market and sell. The Company does expect this trend to continue.
The Company expects to continue to utilize any revenues generated by the
Company to continue its research and development efforts.



     Operating expenses decreased slightly to $13,146 in the second quarter
2000 compared to $17,832 in the same quarter of 1999.  The operating expenses
are larger than the revenues due to the Company's accelerated efforts in
research and development activities and the Company expects these expenses to
stay at the current level or increase for the next twelve months.


     Comparison of the six months ended December 31, 2000 and the six months
     ended December 31, 1999.

     The Company realized revenues of $6,204 from product sales for the six
months ended December 31, 2000, compared to $5,176 in the same period of
1999. The Company did not have any other significant income.

     Administrative expenses increased  during the first six months of fiscal
2000 to $25,932 compared to $6,536 mostly due to professional fees.  The
professional fees consist mainly of consulting fees which increased from
$4,060 in the first six months of fiscal 1999 to $24,217 in the six months
ended December 31, 2000. This increase is primarily due to the increased use
of consultants to assist the Company to accomplish its business plan.  The
Company expects this to continue at a similar rate for the next twelve
months.

     Accounts receivable increased to $13,452 at the six months ended
December 31, 2000, compared to $9,351 in the same period of 1999.  Accounts
payable increased dramatically by $10,573 in the six months ended December
31, 1999, compared to $22,467 in the six months ended December 31, 2000.  The
increase in accounts payable is primarily due to the use of consulting
services.  Finally, the increase in the total deficit from inception through
the six months ending at December 31, 2000, was $336,691 compared to $123,491
for the same period in 1999.

PART II - OTHER INFORMATION

Item 1.  Legal Proceedings

     None.

Item 2.  Changes in Securities

     No instruments defining the rights of the holders of any class of
registered securities have been materially modified, limited or qualified.

     Since the Company's last report for the quarter ended September 31,
2000, the Company has not issued or sold any securities which are not
registered under the Securities Act of 1933.

Item 3.  Defaults upon Senior Securities

     None

Item 4.  Submission of Matters to a Vote of Security Holders

     None

Item 5.  Other Information

     None


Item 6.  Exhibits and Reports on Form 8-K

     (A)  Reports on Form 8-K

     No reports on Form 8-K were filed or required to be filed during the
quarter ended December 31, 2000.

     (B)  Exhibits.  The following exhibits are included as part of this
report:

          None


                                 SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this to be signed on its behalf by the undersigned
thereunto duly authorized.

                                     Novamex USA, Ltd.

September 10, 2001                   By: /s/ Karim Menassa
                                     --------------------------------
                                     President


September 10, 2001                   By: /s/ Jean-Francois Welch
                                     -------------------------------
                                     Secretary